Bristol-Myers Squibb: Leukemia, Myeloid, Acute trials

The registry lists 38 Leukemia, Myeloid, Acute studies with Bristol-Myers Squibb as lead sponsor. 1 are open to participants now and 11 have results posted.

Phase 1 19Phase 2 12Phase 3 2No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid LeukemiaRecruitingNCT06073769
• A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete RemissionActive, not recruitingNCT05197426Phase 2Results posted
• A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromesTerminatedNCT05168202Phase 1Results posted
• A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic SyndromesTerminatedNCT02848001Phase 1Results posted
• An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)CompletedNCT02775903Phase 2Results posted
• A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction ChemotherapyActive, not recruitingNCT02677922Phase 1/2Results posted
• A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02538965Phase 2Results posted
• An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02305563Phase 1/2Results posted
• Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).CompletedNCT01835587Phase 1/2Results posted
• Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete RemissionCompletedNCT01757535Phase 3Results posted
• A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid LeukemiaCompletedNCT01358734Phase 2Results posted
• Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)CompletedNCT01074047Phase 3Results posted
• Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid LeukemiaCompletedNCT07458542
• Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in FranceCompletedNCT06565975
• Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT06419634Phase 1
• An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete RemissionActive, not recruitingNCT05413018Phase 2
• A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)CompletedNCT05218902
• Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic SyndromesTerminatedNCT04951778Phase 1
• A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)CompletedNCT04887857Phase 1
• Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT04789655Phase 1
• A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive TherapyTerminatedNCT04748848Phase 1
• A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid LeukemiaTerminatedNCT04336982Phase 1
• Expanded Access for CC-486Approved for marketingNCT03723135
• A Study of Perpetrator Drug Interactions of Enasidenib in AML PatientsCompletedNCT03720366Phase 1
• Survival in Patients Older Than 60 Years With Newly Diagnosed AML in SpainCompletedNCT03435341
• A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid TreatmentCompletedNCT02921815
• An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the NetherlandsCompletedNCT02891551
• A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)TerminatedNCT02641002Phase 1
• A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.CompletedNCT02450877Phase 2
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Connect® Myeloid Disease RegistryTerminatedNCT01688011
• Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral AzacitidineCompletedNCT01519011Phase 1
• First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell CancersCompletedNCT01120457Phase 1
• Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple MyelomaCompletedNCT00761722Phase 1
• Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT00666497Phase 2
• Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous LeukemiaCompletedNCT00528983Phase 1
• MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory DiseaseTerminatedNCT00374296Phase 2
• A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous LeukemiaCompletedNCT00324220Phase 1/2